HRA indicates health risk appraisal; UBH, United Behavioral Health (a managed behavioral health care company).
Customize your JAMA Network experience by selecting one or more topics from the list below.
Wang PS, Simon GE, Avorn J, et al. Telephone Screening, Outreach, and Care Management for Depressed Workers and Impact on Clinical and Work Productivity OutcomesA Randomized Controlled Trial. JAMA. 2007;298(12):1401–1411. doi:10.1001/jama.298.12.1401
Context Although guideline-concordant depression treatment is clearly effective, treatment often falls short of evidence-based recommendations. Organized depression care programs significantly improve treatment quality, but employer purchasers have been slow to adopt these programs based on lack of evidence for cost-effectiveness from their perspective.
Objective To evaluate the effects of a depression outreach-treatment program on workplace outcomes, a concern to employers.
Design, Setting, and Participants A randomized controlled trial involving 604 employees covered by a managed behavioral health plan were identified in a 2-stage screening process as having significant depression. Patient treatment allocation was concealed and assessment of depression severity and work performance at months 6 and 12 was blinded. Employees with lifetime bipolar disorder, substance disorder, recent mental health specialty care, or suicidality were excluded.
Intervention A telephonic outreach and care management program encouraged workers to enter outpatient treatment (psychotherapy and/or antidepressant medication), monitored treatment quality continuity, and attempted to improve treatment by giving recommendations to providers. Participants reluctant to enter treatment were offered a structured telephone cognitive behavioral psychotherapy.
Main Outcome Measures Depression severity (Quick Inventory of Depressive Symptomatology, QIDS) and work performance (World Health Organization Health and Productivity Questionnaire [HPQ], a validated self-report instrument assessing job retention, time missed from work, work performance, and critical workplace incidents).
Results Combining data across 6- and 12-month assessments, the intervention group had significantly lower QIDS self-report scores (relative odds of recovery, 1.4; 95% confidence interval, 1.1-2.0; P = .009), significantly higher job retention (relative odds, 1.7; 95% confidence interval, 1.1-3.3; P = .02), and significantly more hours worked among the intervention (β=2.0; P=.02; equivalent to an annualized effect of 2 weeks of work) than the usual care groups that were employed.
Conclusions A systematic program to identify depression and promote effective treatment significantly improves not only clinical outcomes but also workplace outcomes. The financial value of the latter to employers in terms of recovered hiring, training, and salary costs suggests that many employers would experience a positive return on investment from outreach and enhanced treatment of depressed workers.
Trial Registration clinicaltrials.gov Identifier: NCT00057590
Depression imposes enormous societal burdens,1-3 with annual US economic costs of tens of billions of dollars due largely to productivity losses.4,5 Indeed, comparative cost-of-illness studies show that depression is among the most costly of all health problems to employers.6-10 Despite evidence that guideline-concordant treatment can be effective,11-21 many depressed workers are untreated or inadequately treated.22-26 Effectiveness trials have demonstrated that organized depression screening and enhanced-care programs can significantly improve treatment and clinical outcomes.27-41 Based on the magnitude of depression-related lost productivity, one might expect employer-purchasers (ie, those who purchase corporate health benefits) to invest in enhanced depression screening-treatment programs. However, widespread uptake has not occurred42,43 due in part to employer-purchasers being unsure of the return-on-investment of such programs.44,45 Few controlled trials have evaluated effects of such programs on work outcomes and those few focused on primary care samples rather than on the workplace samples that would be the focus of employer-based screening, outreach, and disease management efforts.36,41 Without such information, employer-purchasers are likely to remain hesitant to invest in enhanced depression care. In this report, we present the results of a randomized controlled trial designed explicitly to address this issue. The trial examined the impact of depression screening, vigorous outreach, and care management of depressed workers employed by a number of large national firms. The primary outcomes included not only depression symptom relief but also job retention, decreased sickness absence, and increased work productivity.
Participants included 604 depressed workers 18 years and older enrolled in United Behavioral Health (UBH), a large managed behavioral health care company. Participating employers differed in whether UBH was the only behavioral health plan available, coverage criteria, the extent to which workers paid insurance premiums from salaries, and benefit design (co-payment size, visit caps, etc).
Recruitment occurred between January 2004 and February 2005 using a 2-phase procedure. Phase 1 included a health risk appraisal (HRA) survey conducted in 16 large companies from diverse sectors (airline, insurance, banking, public utility, state government, manufacturing) and containing broad distributions of occupations. An informed consent script was followed by a chronic-conditions checklist,46 screen for psychological distress (K-6),47,48 questions about occupation and work performance, and sociodemographics.
Employees whose screen results were positive for possible depression (K-6 score ≥ 9) were invited by an introductory letter and telephone call from a survey interviewer to participate in a second-phase telephone interview that assessed depression more specifically using the Quick Inventory of Depression Symptoms Self-Report (QIDS-SR) version.49-51 An initial informed consent script described the study and its voluntary and confidential nature; respondents were told they might be invited to participate in an innovative treatment program but there were no requirements to accept this or any specific treatments. Respondents with at least moderate depression severity (QIDS-SR score ≥8) were eligible for randomization. Exclusion criteria included: positive responses to Composite International Diagnostic Interview short form52 screening questions for a history of mania or substance dependence (such persons were informed and told to follow-up with a clinician), suicidal ideation or attempts in the prior week (those respondents were immediately connected by telephone to a UBH crisis counselor), and treatment by a mental health specialist in the prior year.
Phase 1 individual-level HRA invitations were sent to 113 843 workers (mainly by e-mail) in 12 of the 16 companies. Of those invited, 35 169 completed at least 1 HRA question, 2358 (7.7%) of respondents had screen results positive for depression, and 1422 consented to baseline eligibility assessments and had UBH coverage (all company employees were screened, not just those with UBH coverage).
In the 4 remaining companies (approximately 150 000 workers) where individual-level contact information was not available, mass e-mail invitations were sent to the entire workforce and individuals provided contact information only in the initial HRA; 11 715 responded by completing at least one HRA question, 942 (10.9%) of respondents had screen results positive for depression, of whom 331 also had UBH coverage and consented to baseline eligibility assessments. A separate enrollment procedure used the UBH member wellness survey of behavioral health symptoms and functional impairments mailed to members who received an authorization for outpatient treatment.53,54 Of 114 635 mailed surveys, 30 402 were completed and returned. Of those who returned the surveys, 6225 individuals agreed to participate in eligibility assessments.
These recruitment and consent procedures, including use of tape-recorded oral informed consent, were approved by Harvard Medical School's Human Subjects Research Committee.
Dispositions of eligible consenting phase 1 participants for whom phase 2 eligibility assessments were attempted are shown in the Figure. Of 604 eligible, 304 were randomized without blocking or stratification to the intervention and 300 to usual care. Randomization was carried out by the survey research firm conducting eligibility assessments with a computerized procedure that classified respondents for eligibility and used a random number generator to assign participants to intervention or usual care. Those assigned to usual care were informed that their responses indicated possible depression and advised to consult with a clinician; they could receive any normally available insurance benefit or service (eg, psychotherapy or pharmacotherapy), just not the additional telephone care management components provided to those in the intervention group.
The structured telephone intervention program (provided without charge to participants who were randomly assigned to receive the intervention) systematically assessed needs for treatment, facilitated entry into in-person treatment (both psychotherapy and antidepressant medication), monitored and supported treatment adherence, and (for those declining in-person treatment) provided a structured psychotherapy intervention by telephone.55 Specific treatments were provided according to both clinical need and participant's willingness to accept treatment.
Care managers were licensed master's degree–level mental health clinicians employed by UBH. Additional training for this study included 12 hours of didactic instruction, role-play, and observed care manager contacts. Care managers also received approximately 60 minutes of supervision each week (from G.E.S., E.J.L., P.S.W., or F.A.) throughout the study period and had approximately 50 to 70 individuals in their caseloads when functioning at capacity.
Initial telephone contacts included a structured assessment of depressive symptoms (Patient Health Questionnaire 9),56 prior treatment, complicating factors (including substance abuse), and motivation for treatment. For all participants with significant depressive symptoms, care managers recommended in-person psychotherapy as well as medication evaluation and provided treatment authorization and referral information. For participants declining in-person treatment, care managers provided a brief motivational intervention57 and asked permission for continued telephone contact. Following initial contacts, all intervention participants were mailed a psychoeducational workbook58 emphasizing behavioral activation, identifying and challenging negative thoughts, and developing long-term self-care plans.
For participants entering in-person treatment, subsequent care manager contacts included structured assessments of depressive symptoms, treatment adherence, and barriers to continuing treatment. As needed, care managers provided feedback and algorithm-based recommendations to treating providers. A UBH psychiatrist was also available for consultation to clinicians if needed. For participants receiving one mode of treatment, adding a second mode was recommended if significant depressive symptoms persisted after 2 months. For participants declining in-person treatment, care managers maintained regular telephone contacts. Intervals between contacts were determined by clinical need, ranging from weekly (for severe depressive symptoms) to bimonthly (for those considered stable or with mild or minimal symptoms).
Intervention participants declining in-person treatment and experiencing significant depressive symptoms after 2 months were offered a structured 8-session cognitive behavioral psychotherapy program.38,55,59 Approximately weekly sessions lasted 30 to 40 minutes and followed the workbook described above. Sessions included assessment of motivation for treatment and motivational enhancement exercises57; focus on increasing pleasant and rewarding activities60; identifying, challenging, and distancing from negative thoughts61,62; and creating a personal self-care plan covering medication use, self-monitoring, and self management skills.63 Booster sessions were scheduled every 4 to 8 weeks to monitor and support progress.
All care management activities were organized and supported by an electronic decision support system. Care manager training and procedural materials are available upon request
Blinded outcome assessments were performed at baseline and at 6 and 12 months by trained survey interviewers at the research firm conducting telephone interviews. Participants were advised not to offer information regarding their intervention status to preserve blinding.
The QIDS-SR is a fully structured assessment50,51 that correlates significantly (r = 0.72) with the 17-item clinician-administered Hamilton Rating Scale (HRSD)64 and has good sensitivity to change.49 QIDS-SR partial item-missing data were imputed using mean imputations (ie, by assigning the mean score obtained from respondents in the same treatment arm with valid scores). Item-missing data occurred in only a small proportion of cases and were unrelated to treatment status.
The World Health Organization Health and Productivity Questionnaire (HPQ) is a fully structured instrument65,66 assessing 4 broad dimensions of work functioning: (1) work hours (absenteeism); (2) job performance, with priming and decomposition questions followed by an anchored global 0-to-10 rating scale that is the measure used to define performance; (3) job turnover (fired, quitting, changing jobs, disability leave); and (4) critical workplace incidents, assessed in open-ended questions about job-related accidents or injuries, other major negative events, and major positive events (eg, receiving a promotion). Validation studies have documented significant associations (r = 0.61-0.87) of HPQ work hours assessments with payroll records66 and job performance assessments with supervisor ratings (r = 0.52)65 and other administrative records (area under the curve, 0.58-0.72).66 The HPQ partial item-missing data occurred in only a small proportion of cases, were unrelated to treatment status, and were imputed using mean imputations.
The care manager record system recorded contacts for recruitment monitoring and telephone psychotherapy. Telephone psychotherapy data were missing for the first 30% of participants and were imputed using multiple imputation.67 Other mental health services were assessed by self-report in the telephone interviews.
All comparisons were made in intent-to-treat analyses (based on original intervention assignment, regardless of treatments received). The propensity score method68 was used to adjust for imperfect randomization in baseline characteristics. A logistic regression equation distinguishing intervention vs usual care groups based on baseline depression severity, absenteeism, job performance, and sociodemographics was used to generate predicted probabilities of intervention assignment. These predicted probabilities were used to weight the data without case-level matching so intervention and usual care groups had comparable distributions of characteristics (results available on request.)
Multiple imputation was used to adjust for some participants not completing either 6-month (35 intervention and 22 usual care) or 12-month (44 intervention and 30 usual care) interviews. Nonrespondents differed from respondents both on sociodemographic variables (nonrespondents were older, less well educated, and more likely to be male) and baseline scores on outcomes (nonrespondents had somewhat higher baseline depression severity and lower work performance). A 2-part process was used to adjust for these differences: (1) estimates were generated for missing values using regression equations with all available data in the baseline and completed follow-up interviews as predictors; and (2) significance tests were adjusted for imputed values being estimated rather than observed using multiple imputation simulation methods.
Intervention effects on depression severity were estimated using multiple imputation multiple linear regression with simulated standard errors. QIDS-SR scores at 6 and 12 months were regressed on a dichotomous predictor for randomization status. Dichotomous measures of symptom improvement (≥50% reduction in QIDS-SR scores) and complete remission (QIDS-SR scores of ≤5) were also examined using multiple imputation multiple logistic regression.
Comparable multiple imputation regression analyses were used to estimate intervention effects on work outcomes. The primary outcome was a composite measure of the number of effective hours worked in the prior 7 days, for which participants no longer working contributed no hours and numbers of hours worked by employed respondents were weighted by job performance (eg, 30 hours worked with a rating of on-the-job performance of 8 out of a possible 10 points was assigned a score of 24 effective hours). Intervention effects on components of this composite (ie, probability of no longer working, number of hours worked among the employed, job performance during hours worked among the employed, and critical workplace incidents) were also examined. The multiple imputation multiple regression analyses estimated intervention effects at 6 and 12 months. We also estimated intervention effects constrained to be equal across these 2 time intervals to increase statistical power. This approach was implemented by pooling data across the 2 wave-pairs and including a dummy variable to distinguish the baseline-to-6-month panel from 6-to-12-month panel.
All linear regression coefficients (β) and odds ratios (ORs) from logistic regression equations were adjusted for outcomes at the prior assessment; expected hours of work at the prior assessment; and respondent age, sex, and education. In post hoc subgroup analyses, intervention effects were examined in subsamples defined by initial depression severity (moderate and severe cases corresponding to QIDS-SR score ≥11) and recruitment procedure (HRA vs UBH member wellness survey).
Power calculations indicated a sample of 300 per group would be needed to detect a difference of 0.2 SD of work productivity (power = 0.8, 2-sided P = .05) with 20% loss to follow-up. The minimum detectible effect size of a 0.2 SD was based on previous evidence that low to moderate intensity depression interventions yield effects on clinical outcomes of an SD of approximately 0.3335,39,40 and that clinical improvements are correlated with an SD of approximately 0.60 with improvements in work performance.13 Analyses were performed using SAS statistical software version 9.1.3 (SAS Institute Inc, Cary, NC).
Propensity score weights adjusted for baseline differences after randomization (Table 1), including the somewhat younger age, lower proportions of women and college graduates, and lower baseline depression severity in the intervention vs usual care group.
When compared with workers meeting study criteria in the nationally representative National Comorbidity Survey Replication,69 trial participants were somewhat older, more likely to be women, more educated, somewhat less depressed, and worked somewhat more hours, possibly reflecting the fact that the trial sample was confined to full-time workers in large national firms (results available upon request).
QIDS-SR scores were significantly lower in the intervention than in the usual care group by 6 months, with an effect size (β = −1.0) of approximately one-third of an SD (Table 2). This advantage was retained at 12 months (β = −1.1). The proportion of participants whose symptoms improved substantially (50% QIDS-SR improvement) was also significantly higher among the intervention than the usual care group but not until the 12-month assessment (30.9% vs 21.6%; OR, 1.7; 95% CI, 1.1-2.5). The proportion of participants experiencing recovery (QIDS-SR score, ≤5) was also significantly higher in the intervention than the usual care group but not until 12 months (26.2% vs 17.7%; OR, 1.7; 95% CI, 1.1-2.4).
Post hoc subgroup analysis failed to find significant differences in intervention effects among participants with mild (QIDS-SR score, ≤10) vs moderate or severe (QIDS-SR score, ≥11) baseline depression and among participants recruited through HRAs vs the UBH member wellness survey (results available upon request).
Scores on the summary effective hours worked measure were significantly higher in the intervention than usual care group at 6 (β = 3.0) and 12 (β = 3.3) months (Table 3). The 2.0 coefficient for hours worked among the employed means that workers in the intervention group worked an average of 2 more hours per week than workers in the usual care group, which is equivalent to an annualized effect of more than 2 weeks of work (ie, 2 hours per week × 48 work weeks in the year). This overall effect was due to significant improvements in job retention (92.6% vs 88.0% by 12-month; OR, 1.7; 95% CI, 1.0-3.3) and hours worked among employed respondents (β = 2.0). Job retention was defined from the employee perspective (ie, the employee's continuing to hold a job) rather than from the employer perspective (ie, the employee's continuing to work for the same employer). Subsequent analysis found that, among participants employed at follow-up, the proportion working for the same employer was unrelated to intervention. However, as overall job retention was significantly higher in the intervention group, the unconditional proportion of baseline respondents working for the same employer was higher in the intervention group than the usual care group (results available on request).
Further analysis showed that extreme values did not explain the significant intervention effect on hours worked among employed respondents, for this effect remained significant when the outcome variable was transformed using a square root transformation (P = .049). Decomposition showed, furthermore, that the overall effect on hours worked was due to an effect on the number of hours worked controlling for expected work hours (β = 1.7, P = .04) rather than on number of expected work hours (β = 0.6, P = .18). The intervention effect on job performance, in comparison, was not significant (β = 0.2, P = .11), although it was consistently positive. No significant effects were found, finally, on critical workplace incidents or on taking a job with another employer (results available upon request). Subgroup analysis failed to find significant differences in intervention effects between mild vs moderate or severe cases or those recruited through HRAs vs the UBH member wellness survey (results available on request).
Intervention group participants were significantly more likely than those in usual care to receive any mental health specialty treatment (OR, 1.6; 95% CI, 1.1-2.3), but somewhat less likely to obtain any depression treatment in primary care (OR, 0.7; 95% CI, 0.5-1.0) or nonmedical settings (OR, 0.6; 95% CI, 0.4-1.1; Table 4). The mean number of treatment contacts across all settings (including care manager contacts) was nearly twice as large in the intervention vs the usual care group (12.7 vs 6.5; t = 5.7; P < .001). Of those randomized to receive the intervention, 50% completed initial care management contact by 8 days, 75% by 22 days, 90% by 114 days, and 9% were never reached.
The results suggest that enhanced depression care of workers has benefits not only on clinical outcomes but also on workplace outcomes. Although direct comparison to earlier studies is difficult because our trial is the first conducted exclusively among employed people, it is noteworthy that our effect size on clinical improvement (approximately one-third of an SD on the QIDS-SR distribution) is similar to earlier primary care trials using low to moderate intensity interventions.35,39,40 Our finding of similar effects among less severe and more serious cases is consistent with earlier primary care trials41,70 and suggests the intervention has benefit to a wide spectrum of depressed workers.
The significant 2.6-hour improvement per week in overall work functioning among intervention participants is due to a combination of increased job retention and increased hours worked among the employed. Earlier analyses of either primary care depressed patients41 or working subsamples of such patients71 have found generally comparable effects on retention and absenteeism. Although we did not find significant effects on work performance among the employed by 1 year, 1 primary care trial that followed up patients for 2 years did.36 The apparent effects on absenteeism and performance among the employed in our trial may also have been downwardly biased if the intervention led to retention of employees with more absences or worse performances. Unfortunately, direct comparisons with these earlier studies are difficult due to differences in intervention intensity, follow-up, and stratum definitions.
Formal evaluation of our intervention's return on investment to employers is not currently possible because the latter requires information not yet available on duration of improvements, disability payments, overall health care expenditures, and hiring and training costs. However, the $1800 annualized value of higher mean hours worked among intervention participants retaining their jobs (assuming the median annual salary in the US civilian labor force) by itself far exceeds the $100 to $400 outreach and care management costs associated with low- to moderate-intensity interventions of the sort we implemented38,39; these saving might also exceed or closely approximate the costs of approximately 10 additional mental health specialty visits made by intervention participants over the course of a year.
These last observations suggests that outreach and enhanced care for depressed workers might be better conceptualized as an opportunity to invest in improving the productive capacity of workforces (referred to by employers as “human capital investments”) than as workplace costs.72,73 That the intervention also had positive impacts on job retention and the costs of hiring and training new workers are typically high1 reinforce this interpretation.74 However, it is important to recognize that these workplace benefits would not be realized by all employers because hiring and training costs and the extents to which employees are paid—piecemeal, hourly, or by salary—vary.
The intervention had modest effects on self-reported use of treatments, consistent with earlier trials of low-intensity interventions.38,39 However, intervention participants received twice as many contacts as usual care participants when care manager contacts were included (12.7 vs 6.5, t = 5.7, P < .001) and were 70% more likely to receive any mental health specialty treatment. Although it is difficult to identify active components from a trial with a single intervention group, the finding that intervention participants received more mental health specialty treatment is noteworthy in light of other data suggesting that mental health specialty care is more likely to meet evidence-based recommendations than treatments in other sectors.25 A recent meta-regression of 28 depression collaborative care trials is also instructive in that it identified 3 “active ingredients”: systematic screening to identify patients (vs other means such as clinician referral), use of mental health professionals as care managers, and regularly planned care manager supervision.27 All 3 elements were included in our intervention. The telephone cognitive behavioral therapy may also have had similar beneficial effects as an earlier trial that found a higher proportion of patients whose care management included telephone cognitive behavioral therapy had experienced depression improvement than those who had received care management alone.38
Several potential technical limitations are noteworthy. First, the QIDS-SR might have misclassified cases, although clinical reappraisal studies show it has high concordance with blinded clinician assessments.49-51 Second, the HPQ might have been systematically biased,75 although significant associations between HPQ scores and independent administrative or archival records of absenteeism and work performance have been documented across a broad range of occupations.65,66 Third, workers who participated in our initial screening phase may have had a different prevalence, severity, or impairment associated with their depression than nonparticipants. Although we had no way to evaluate this possibility, a prior study found initial participants in HRA screenings were comparable—in terms of depression severity, work impairments, and associations between the two—with initial nonrespondents who participated only after more intensive recruitment efforts.76 Fourth, the generalizability of our findings is unclear because trial participants had less severe depressions and a different sociodemographic profile than a nationally representative sample of depressed workers. Although we found no differences in intervention effects across levels of depression severity or method of recruitment, such differences could exist across other subgroups (eg, white-collar vs blue-collar workers) and have relevance to employers whose workforces vary in these characteristics.
Potential conceptual limitations also need to be considered. Simple human capital metrics such as absenteeism and job performance might overestimate true costs to employers, as would happen if unperformed work during absences is made up by coworkers or the absent worker upon return.77 However, it is also possible that the burdens of depression to employers are underestimated herein because other costs, such as for hiring temporary workers, paying coworkers overtime, and adverse effects on coworkers' productivity were not considered.78 Likewise, we did not assess intervention effects on outcomes such as suffering, marital stability, caregiver burden, and employee contributions outside the workplace that could have value from a societal perspective and might lead to long-term improvements in productive capacity.79 An exclusive focus on work outcomes might devalue benefits of intervening among groups not in the workforce (eg, the elderly) or in low-wage occupations, emphasizing that health care resource allocation decisions need to consider a societal as well as employer perspective.80 Within the constraints of these limitations, this study suggests that enhanced care for depressed workers can have benefits for employers that go beyond improved health and diminished suffering in their workforces and extend to increased work productivity. Further study is needed to determine whether intervention costs are offset by these workplace benefits and the variation in this offset across different employment settings.72,73,81 Toward this end, it is noteworthy that increased depression treatment among intervention participants was largely provided through telephone contacts with care managers and not provided through more expensive in-person visits with traditional clinicians. We also did not consider whether the intervention offsets any greater general medical utilization associated with depression, as has been observed in earlier primary care trials.32,34,35,82 Likewise, availability of Web-based, e-mail, and interactive voice-recognition technologies should ensure that the costs of screening and recruiting depressed workers into interventions are low.83 These features may be critically important to potential purchasers, who are not just sensitive to interventions' returns on investment but also to their absolute costs and impacts on per member per month charges.44 Attention to these issues in future research is needed to ensure that successful programs of outreach and enhanced depression treatment are widely disseminated.45
Corresponding Author: Philip Wang, MD, DrPH, Division of Services and Intervention Research, National Institute of Mental Health, 6001 Executive Blvd, Room 7141, MSC 9629, Bethesda, MD 20892-9629 (email@example.com).
Author Contributions: Drs Wang and Kessler had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Wang, Simon, Avorn, Azocar, Ludman, McCulloch, Kessler.
Acquisition of data: Wang, Simon, Azocar, Ludman, McCulloch, Kessler.
Analysis and interpretation of data: Wang, Simon, Azocar, Ludman, McCulloch, Petukhova, Kessler.
Drafting of the manuscript: Wang, Simon, Avorn, Azocar, Ludman, McCulloch, Petukhova, Kessler.
Critical revision of the manuscript for important intellectual content: Wang, Simon, Avorn, Azocar, Ludman, McCulloch, Petukhova, Kessler.
Statistical analysis: Wang, Simon, Petukhova, Kessler.
Obtained funding: Wang.
Administrative, technical, or material support: Wang, Simon, Azocar, Ludman, McCulloch.
Study supervision: Wang, Simon, Ludman, Azocar.
Financial Disclosures: Dr Kessler reports consulting for AstraZeneca, Bristol-Myers Squibb, Eli Lilly & Co, GlaxoSmithKline, Pfizer, and Wyeth and reports receiving research support for his epidemiological studies from Bristol-Myers Squibb, Eli Lilly, Ortho-McNeil, Pfizer, and the Pfizer Foundation. Dr Azocar and Ms McCulloch are both employees of United Behavioral Health and report holding stocks and options from United Health Group. No other authors reported financial conflicts.
Funding/Support: The research reported herein was supported by grant R01 MH61941 from the National Institute of Mental Health (Dr Wang), grant 048123 from the Robert Wood Johnson Foundation (Dr Wang), and an unrestricted educational grant that supported earlier pilot work of this study from the John D. and Catherine T. MacArthur Foundation.
Role of the Sponsor: None of these organizations had any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.